HER2-positive breast cancer, intrinsic subtypes, and tailoring therapy

J Natl Cancer Inst. 2014 Aug 19;106(8):dju212. doi: 10.1093/jnci/dju212. Print 2014 Aug.
No abstract available

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Antibodies, Monoclonal, Humanized / pharmacology
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / therapeutic use
  • Biomarkers, Tumor / analysis*
  • Breast Neoplasms / chemistry
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / pathology*
  • Female
  • Humans
  • Receptor, ErbB-2 / analysis*
  • Receptor, ErbB-2 / antagonists & inhibitors
  • Trastuzumab

Substances

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Biomarkers, Tumor
  • ERBB2 protein, human
  • Receptor, ErbB-2
  • pertuzumab
  • Trastuzumab